GLSI
Greenwich LifeSciences, Inc. · Healthcare
22.00
0.14%(-0.03)
Market OpenLast Updated: — ET
52W L: $7.7852W H: $34.10
$21.97
CHG-1.41 (-6.03%)
H$34.99
L$20.65
VOL3.4M
GLSI (1h)
Greenwich LifeSciences, Inc. · Healthcare
STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data.
Greenwich LifeSciences (NASDAQ: GLSI - Get Free Report) is projected to post its results after the market closes on Tuesday, March 31st. Analysts expect Greenwich LifeSciences to post earnings of ($0.33) per share for the quarter. Greenwich LifeSciences Price Performance Shares of NASDAQ GLSI opened at $25.34 on Friday. Greenwich LifeSciences has a 1 year low
STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US.
STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the upcoming AACR Meeting 2026.
STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided a preliminary update showing a continued reduction in the recurrence rate in the fully enrolled, 250 patient, open label non-HLA-A*02 arm of FLAMINGO-01.
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01.
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
1,800 SH @ $29.83
2026-01-13
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
2,900 SH @ $27.54
2026-01-12
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
4,300 SH @ $21.36
2025-12-31
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
2,900 SH @ $21.73
2025-12-30
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
4,100 SH @ $12.62
2025-12-18
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
4,600 SH @ $8.37
2025-11-25
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
100,000 SH @ $8.20
2025-11-13
Patel Snehal
director, 10 percent owner, officer: CEO and CFO
10,600 SH @ $8.43
2025-11-07